ERD

Periodic Reporting for period 5 - ONCOINTRABODY (Targeting common oncogenes with intracellular monobodies)

Project: ONCOINTRABODY

Updated at: 03-08-2024

Show more information

Project acronym ONCOINTRABODY

Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Synthesis of the <scp>l</scp>- and <scp>d</scp>-SH2 domain of the leukaemia oncogene Bcr-Abl

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Monobodies as possible next-generation protein therapeutics – a perspective

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Monobodies as enabling tools for structural and mechanistic biology

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Improving the pharmacokinetics, biodistribution and plasma stability of monobodies

Project: ONCOINTRABODY

Updated at: 27-04-2024

Show more information

Project acronym ONCOINTRABODY

Resources

Selected filters:

Periodic Reporting for period 5 - ONCOINTRABODY (Targeting common oncogenes with intracellular monobodies)

Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly

Synthesis of the <scp>l</scp>- and <scp>d</scp>-SH2 domain of the leukaemia oncogene Bcr-Abl

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies

Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains

Monobodies as possible next-generation protein therapeutics – a perspective

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase

Monobodies as enabling tools for structural and mechanistic biology

Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins

Improving the pharmacokinetics, biodistribution and plasma stability of monobodies